Eli Lilly and Company
@EliLillyandCo
Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad)
加入 July 2010
1.2K 正在关注 145.5K 粉丝
NEW Phase 3 data today at #ADA2026#: Lilly's investigational triple agonist met all primary endpoints in TRIUMPH-1. Patients on the 12 mg dose lost an avg of 70 pounds (28.3%) over 80 weeks. Read more:
显示更多
